PANDA Therapeutics completes Venture Kick’s final funding stage
A CHF100,000 convertible loan brings programme support to CHF150,000 for the Alzheimer’s therapy developer.
Venture Kick announced PANDA Therapeutics’ completion of its final funding stage on 31 August 2026. The CHF100,000 Stage III convertible loan brings total support across the programme’s three stages to CHF150,000.
The Zurich-based biotech will use the support to establish operations and an advisory board, prepare manufacturing and regulatory plans, and develop pharmaceutical partnerships. PANDA is developing an antibody-based approach intended to target several protein aggregates involved in Alzheimer’s disease.
Use of funds
Establish operations and advisory board
Prepare manufacturing, intellectual property and regulatory plans
Develop pharmaceutical partnerships